Posted on: March 28, 2021 Posted by: Betty Lee Comments: 0


Insiders stated the US biotech firm was delaying signing a contract with the EU over manufacturing considerations. However Brussels critics recommended the EU’s ongoing row with Anglo-Swedish pharma group AstraZeneca had led to the cautious strategy from Novavax executives.

Tory MP Andrew Bridgen stated: “The UK has signed a 60 million dose contract with NovaVax for manufacturing within the UK however NovaVax has delayed concluding a take care of the EU citing considerations over manufacturing.

“Given the way in which the bloc has handled AstraZeneca I’m not stunned.

“Actions have penalties. That is rebounding on them.”

The contract delays may additional complicate the EU’s chaotic vaccination technique because the bloc had deliberate to signal a deal early this yr for at the very least 100 million doses of Novavax’s vaccine, with an choice for an additional 100 million.

A Brussels supply stated the corporate had postponed signing a deal for weeks, citing authorized points in conferences with the bloc’s vaccine negotiators.

The official stated: “They’re slowing down the method of ending the contract.”

He stated executives had advised officers the delay was essential as a result of the corporate was having manufacturing issues.

READ MORE:Brexiteer accuses EU of politically motivated assaults on AstraZeneca

A Novavax spokeswoman stated talks with the EU over a provide deal had been persevering with however declined to say extra concerning the discussions.

She stated the corporate was working “via some pandemic-related uncooked supplies provide shortages”, with out giving particulars.

The European Fee, which coordinates talks with vaccine makers, has declined to remark.

The EU’s immunisation marketing campaign is lagging far behind these in Britain and the US whereas a 3rd wave of infections engulfs the continent.

The European Union has tightened its guidelines on vaccine exports, giving it better scope to dam shipments to international locations with larger inoculation charges corresponding to Britain, or which aren’t sharing doses they produce.

Mr Breton stated: “In fact, AstraZeneca has been a difficulty. We had an issue with this firm.

“We have now the instruments and can ensure every part stays in Europe till the corporate will come again to its commitments.”

Of 300 million doses because of be delivered to EU international locations by the top of June, AstraZeneca goals to ship solely 100 million.





Supply hyperlink

Leave a Comment